Abstract We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 ± 7.07 years old. The median duration of the disease was 7.43 ± 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 ± 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 ± 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up.
Abbreviations

RA
Rheumatoid arthritis DAS28-CRP The 28 joint count Disease Activity Score using C reactive protein CRP C-reactive protein TNF-a Tumor necrosis factor alpha ACR Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive inflammatory synovitis and erosion of articular cartilage and marginal bone that generally begins early in the disease course [1] . Although the pathophysiology of RA is not well understood, the proinflammatory cytokine tumor necrosis factor (TNF)-a plays an important role in the pathogenesis of RA, and it is a prime target for directed biologic agents [2] . Two TNF inhibitors, infliximab [3] (75% human and 25% mouse peptide sequences, monoclonal antibody to TNF-a) and etanercept [4] (a recombinant, human, TNF receptor-Fc fusion protein), were already commercially available. The first fully human (100% human peptide sequences) therapeutic monoclonal antibody that blocks TNF-a, adalimumab (D2E7; Abbott Laboratories, Abbott Park, IL), was approved for use and has been extensively studied in clinical trials for treatment of RA [5] . To date, study authors have reported the short-term efficacy of adalimumab in patients with RA. In Japan, adalimumab was approved to be used for RA patients in 2007, and the efficacy and safety were reported by Miyasaka et al. [6] . However, there has been no report about the long-term efficacy of adalimumab for Japanese RA patients. The objectives of this study were to assess the sustained efficacy of adalimumab in long-term monotherapy for Japanese patients and to evaluate the long-term safety and tolerability of adalimumab given subcutaneously. This is the first report of the long-term follow-up data (220 weeks) of six RA cases treated with adalimumab monotherapy in Japan. This study was a multicenter, open trial of adalimumab given as monotherapy performed from October 2002 through April 2008. We treated 6 patients with RA, each of whom fulfilled the 1987 revised American College of Rheumatology (ACR) criteria [7] for 3 months or more and had C12 tender joints and C10 swollen joints (excluding distal interphalangeal joints). They also had a C-reactive protein (CRP) concentration C2 mg/dl and a Disease Activity Score 28 (DAS28) C3.2, despite receiving standard anti-rheumatic treatment including at least one conventional Disease Modifying Anti-Rheumatic Drug (DMARD). Prior therapy with DMARD was discontinued at least 28 days before entry in the present study and returned for baseline visit within 42 days. The patients who were treated with biologic agents, including anti-CD4 antibody, within 6 months or prior treatment with any TNF antagonist or an alkylating agent were excluded. They gave their informed consent to the protocol, which was approved by the Institutional Review Board of Nagasaki University. Table 1 summarizes the profiles of the 6 RA patients. None of the patients had received prior therapy with biologic agents. Patients were injected adalimumab by a physician at 20, 40, or 80 mg subcutaneously every other week for 220 weeks. Patients stopped taking current antirheumatic therapy, including any DMARDs, 28 days before starting this treatment. They were allowed to continue glucocorticoids (prednisolone equivalent B10 mg/ day) and non-steroidal anti-inflammatory drugs, provided that the dosage regimens were stable from 28 days before starting the treatment to the end of the treatment. If the treatment was not effective, the doses of adalimumab were increased (cases 1 and 2, 20-40 mg at week 22; case 6, 40-80 mg at week 16). In case 5, the dose was decreased from 80 to 40 mg at week 22 because of the good response.
The effectiveness of adalimumab for 6 cases of RA patients was assessed at weeks 4, 16, and 28, and every 12 weeks in the extension phase using tender joint counts (TJC), swollen joint counts (SJC), visual analog scale (VAS) score, C-reactive protein (CRP), and DAS28-CRP (calculated using CRP concentration and evaluation of 28 joints) (Fig. 1 ). All 6 patients were women, and the median age was 54.0 ± 7.07 years old. The median duration of the disease was 7.43 ± 11.1 years, and the median score of DAS28-CRP at entry was 5.35 ± 0.69. Three patients were able to continue receiving adalimumab monotherapy for 220 weeks successfully. The median score on DAS28-CRP became 3.52 ± 1.61 at week 24, 2.79 ± 1.15 at week 48 and had decreased to 1.89 ± 0.75 by week 220. All three patients who could continue this treatment for 220 weeks showed a response for 220 weeks and achieved clinical low disease activity (DAS28-CRP \2.7).
Two patients withdrew because of lack of efficacy (case 1 discontinued at week 46; case 6 discontinued at week F Female, BW body weight, DMARDs disease modifying anti-rheumatic drugs, TJC tender joint count, SJC swollen joint count, CRP C-reactive protein, VAS visual analog scale, mHAQ modified Health Assessment Questionnaire, DAS28-CRP the 28 joint count Disease Activity Score using C-reactive protein 48), and one patient withdrew because of adverse events (case 5 discontinued at week 88 because of non-Hodgkin lymphoma) ( Table 2) . We report the effectiveness of adalimumab monotherapy for 6 Japanese RA patients followed up for 220 weeks. In this study, we found its effectiveness last long time even in 220 weeks. The efficacy and safety of adalimumab as monotherapy in 544 RA patients for 26 weeks were previously reported. In the previous study, patients were treated with monotherapy of adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, or 40 mg weekly, or with a placebo. After 26 weeks, patients were treated with adalimumab 40 mg every other week or 40 mg weekly. The groups achieved ACR20 in 46 and 53.4% of patients, respectively. These response rates were significantly better than that in the placebo group (19.1%) [8] . Recently, Miyasaka et al. [6] reported that in the Clinical investigation in Highly disease-affected rheumatoid Arthritis patients in Japan with Adalimumab applying staNdard and General Evaluation (CHANGE) study, adalimumab 20, 40, and 80 mg were safe and effective in Japanese patients. All adalimumab treatment groups achieved statistically significantly higher ACR20 responses (28.7% in the 20 mg group, 44.0% in the 40 mg group, and 50.6% in the 80 mg group) compared with the placebo group (13.8%) during 24-week follow-up. In our patients, the median score of DAS28-CRP was decreased from 5.35 ± 0.69 to 3.52 ± 1.61 at week 24. Afterward the efficacy continued, and the median score on DAS28-CRP had decreased to 1.89 ± 0.75 by week 220. We demonstrated 220 week long-term follow-up data about the efficacy of adalimumab monotherapy for the first time in Japan. The efficacies at week 220 were better than those at week 24. Four of 6 patients achieved DAS28 \2.7, meaning clinical low disease activity at 4 weeks after starting treatment in case 2, at 16 weeks in case 3, and at 64 weeks in cases 4 and 5. Three patients continued this treatment under remission state until week 220; one patient (case 5) discontinued the treatment because of suffering from non-Hodgkin lymphoma. The Anti-TNF Research Study Program of the Monoclonal Antibody D2E7 in Rheumatoid Arthritis (ARMADA) trial [9] , a 6-month, placebo-controlled, phase II/III study, demonstrated significant reductions in signs and symptoms of RA, and improvement in physical function in response to combined therapy with MTX and adalimumab. In their study, the clinical response and remission were sustained in patients with RA during 4 years of treatment with adalimumab [10] . Although our patients were not treated with MTX, 3 patients showed a good response to adalimumab monotherapy. Three patients were discontinued because of an adverse event in one and no response in two. One (case 6) of two non-responder patients was anti-adalimumab antibody (AAA)-positive. Bartelds et al. [11] reported that lack of response to adalimumab is probably caused by the formation of AAA. AAA normally appears at low levels but at high frequency, especially in Japanese RA patients.
Regarding adverse events, 2 of 6 patients (33%) experienced injection site reaction, and 2 of 6 patients had infectious adverse events, including nasopharyngitis and common colds (33%). Although the number of patients was small in our study, the occurrence of injection site reaction and infectious adverse events were almost the same as in a previous report [6] , even during a 220-week follow-up. We did not experience tuberculosis or opportunistic infections. There were no reports of tuberculosis in the adalimumab treatment groups in the 24-week follow-up CHANGE study in Japan [6] , but there was a 4-to 7-fold increased risk of reactivation of latent tuberculosis in patients using TNF inhibitors [12, 13] . Case 5 was forced to discontinue treatment because of non-Hodgkin lymphoma in week 88. Recent reports have suggested a slight increase in the risk of lymphoma, particularly in patients with RA [14] . In the CHANGE study, malignancies were reported in two patients only in the placebo group during the double-blinded period. On the other hand, a recent metanalysis involving infliximab and adalimumab demonstrated an increased risk of lymphoproliferative disease and malignancies in patients treated with these agents [15] . Therefore, we have to consider both the risk and the benefit when we use TNF antagonists for RA patients.
In conclusion, among patients with RA for whom previous anti-rheumatic treatment had failed, adalimumab monotherapy achieved significant and sustained improvements in disease activity for a long time and improved physical function while being safe and well tolerated. Our study has a limitation, because the number of patients is small. Next, we plan to increase the number of patients and examine when these patients should discontinue the treatment, which needs further investigation.
